Company news

Skye Bioscience, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

September 22, 2024

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

September 2, 2024

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

August 25, 2024

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

August 21, 2024

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

August 8, 2024

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

July 23, 2024

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

July 10, 2024

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

July 10, 2024

Skye Bioscience Uplists to The Nasdaq Global Market

April 9, 2024

Skye Bioscience Announces $40 Million Private Placement Equity Financing

March 10, 2024

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

March 3, 2024

Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

February 25, 2024

Skye Bioscience to Present at Oppenheimer Investor Conference

February 6, 2024

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

January 28, 2024

Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

January 8, 2024

Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

December 10, 2023

Skye Bioscience Responds to OTC Markets Promotional Policy

December 7, 2023

Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa

December 4, 2023

Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion

November 27, 2023

Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit

November 20, 2023

Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma

October 24, 2023

CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

October 19, 2023

Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial

September 26, 2023

Skye Bioscience Announces Participation at Upcoming Investor Conferences

September 21, 2023

Skye Bioscience Reverse Stock Split to Be Effective on September 8th

September 6, 2023

Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody

August 20, 2023

Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

August 13, 2023

Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion

July 12, 2023

Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial

July 5, 2023

Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion

June 11, 2023

Skye Bioscience to Present at LD Micro Invitational XIII

June 4, 2023

Skye Bioscience Receives Positive Safety Review of Fifth Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion

June 1, 2023

Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist

May 16, 2023

Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion

May 14, 2023

Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist

April 26, 2023

Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion

April 3, 2023

Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journal

April 2, 2023

Skye Bioscience Receives Human Research Ethics Committee Approval to Start Multiple Ascending Dose Arm of Phase 1 Study of SBI-100 Ophthalmic Emulsion

March 14, 2023

Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion

March 6, 2023

Skye Bioscience moving ahead with SBI-100 clinical trial after positive safety review

February 23, 2023

Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study

February 22, 2023

Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors

February 15, 2023

Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment

February 14, 2023

Skye Bioscience Doses Second Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion

February 12, 2023

Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion

February 1, 2023

Skye Bioscience Achieves Positive Safety Review of SBI-100 Ophthalmic Emulsion After Phase 1 First Cohort

January 30, 2023

Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion

January 26, 2023

Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE

December 19, 2022

Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion

December 15, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 41 decks. Every deck is listed under its year.